Adamax
| Category | Compounds |
|---|---|
| Also known as | Adamax Peptide |
| Last updated | 2026-04-14 |
| Reading time | 3 min read |
| Tags | nootropicpolypeptiderussian-researchcognition |
Overview
Adamax is a polypeptide research compound discussed primarily in nootropic communities as a composite or hybridized agent drawing on concepts from Russian neuropeptide research traditions that produced Semax and Selank. Published primary literature on Adamax specifically is limited compared to better-characterized neuropeptides, and much of what is discussed online is derived from a small set of sources.
Because of this, Adamax is most useful to understand in the context of the broader family of ACTH- and tuftsin-derived research neuropeptides, alongside NA-Semax and NA-Selank. Discussion tends to focus on potential cognitive, attention, and neuroprotective endpoints similar to those described for Semax, with some sources attributing additional effects that overlap with the anxiolytic profile of Selank.
Adamax is a research compound. Users investigating it in a research context often cross-reference P21 peptide, Cerebrolysin, and Dihexa as related neurotrophic or cognitive peptides.
Structure / Chemistry
Adamax is described as a short polypeptide, but precise sequence disclosures in publicly available English-language literature are sparse. Discussions generally place it in the class of short regulatory peptides with modifications intended to improve pharmacokinetic stability, similar in spirit to the acetyl-amidate modifications used in NA-Semax.
Mechanism of Action
Proposed mechanisms overlap with those attributed to other short regulatory peptides in the Russian research tradition: modulation of BDNF and other neurotrophins, effects on monoaminergic tone, and influence on stress-response and attention circuits. In the absence of extensive primary data, mechanistic claims should be treated as hypotheses rather than established findings.
Research Summary
| Area | Finding | Reference |
|---|---|---|
| Class context | ACTH/tuftsin-inspired regulatory peptides | Ashmarin et al., Pathophysiology 2005 |
| Neurotrophin parallels | BDNF/NGF modulation in related peptides | Dolotov et al., Neurosci Lett 2006 |
| Anxiolytic parallels | Selank-family anxiolytic-like profiles | Semenova et al., Bull Exp Biol Med 2010 |
| Cognitive tasks | Short peptide nootropic effects in rodents | Multiple Russian research group reports |
| Stability design | Acetyl/amide stabilization in short peptides | Shevchenko et al., peptide chemistry reports |
Pharmacokinetics
Publicly available pharmacokinetic data on Adamax specifically are limited. By analogy with related stabilized short peptides, biological activity is likely longer than that of unmodified Semax or Selank, but specific half-life and bioavailability values are not well established in the English literature. Intranasal administration is the common route discussed.
Common Discussion Topics
- Scarcity of primary literature compared to Semax and Selank.
- Whether Adamax is best viewed as a distinct molecule or a research reformulation.
- Potential overlap with both nootropic and anxiolytic neuropeptide classes.
- Intranasal administration and absorption questions.
- Interpretation caveats given limited public English-language data.
Related Compounds
Sourcing research-grade compounds
Obtaining high-purity, research-grade Adamax requires verified and trusted suppliers with third-party COA testing and transparent sourcing practices.
White Market Peptides — Verified Supplier →Join the discussion
See how the community is discussing Adamax. Share your experience, ask questions, and explore protocols on PepAtlas.
Related entries
- Cerebrolysin— A porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids, approved in over 40 countries for stroke, traumatic brain injury, and dementia, though not FDA-approved in the United States.
- N-Acetyl Semax Amidate— N-Acetyl Semax Amidate is a modified analog of Semax with N-terminal acetylation and C-terminal amidation designed to increase stability and potency.
- P21 Peptide— P21 is a CNTF-derived tetrapeptide designed to mimic the active region of ciliary neurotrophic factor, studied for neurogenesis and Alzheimer's disease models.
- Selank— A synthetic heptapeptide analog of the immunomodulatory peptide tuftsin, developed in Russia as an anxiolytic and nootropic with additional immunomodulatory properties.
- Semax— A synthetic heptapeptide analog of ACTH(4-10) developed in Russia as a nootropic and neuroprotective agent, studied for cognitive enhancement, stroke recovery, and BDNF modulation.